Search PubMed⌕ Search

Biomedical subjects

A Claudy

Publications and source records attributed to A Claudy.

At least 163 records · Page 9Linked to original sources
PubMed1989

[Scleroderma and thyroid diseases].

The authors report a prospective study of the thyroid function of 18 consecutive patients with systemic scleroderma and 7 patients with morphea. A history was taken and patients were examined for thyroid disease. The patients were tested for free thyroxin, TSH, cholesterolemia, circulating TeBG, anti-microsomial and anti-thyroglobulin antibodies and had a TRH test. The incidence of thyroid diseases was correlated with an age and sex-matched control population consisting of 2,534 subjects of the Loire department. None of the patients with morphea had a history of thyroid pathology and the thyroid screenings were within normal limits. A familial history of thyroid disease was found in 7 out of 18 patients with systemic scleroderma, and 8 out of 18 patients had a thyreopathy (one Hashimoto's disease, one Graves' disease, one toxic adenoma, one hypothyroidism, two euthyroid goiters, two nodular thyroids). The TRH test only revealed a toxic adenoma. A thyroid disease preceded systemic scleroderma in 5 out of 18 cases with delays ranging from 1 to 38 years. In 3 cases, the thyroid disease occurred within two years after the onset of systemic scleroderma. The prevalence of thyroid disease was significantly higher than in a comparable population sample of subjects from the same geographic region (p less than 0.01). The authors review the literature and discuss the physiopathologic relationships between the two clinical entities. The authors suggest to perform a thyroid screening (ultrasensitive TSH assay) on all patients with systemic sclerosis and especially on those whose clinical follow-up is atypical and on those with a familial and/or personal history of thyroid disease.

Aged↗
PubMed1988

Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis.

A randomized double-blind study was designed with 65 patients in order to clarify two points: (1) does addition of a retinoid to psoralen-ultra violet A photochemotherapy (PUVA) of severe psoriasis decrease the UVA energy required to achieve remission, and (2) is there a difference between two retinoids, i.e. etretinate and acitretin. Acitretin-PUVA treatment was significantly superior to placebo-PUVA with respect to several items (decrease in lesional scores after 6 weeks of therapy, number of PUVA exposures, and total dose of UVA until remission). There were also differences between the etretinate-PUVA and placebo-PUVA groups, but only the decrease in lesional scores reached statistical significance.

Acitretin↗
PubMed1987

Collagen biosynthesis in a case of epidermolysis bullosa dystrophica recessiva.

Collagen metabolism was studied in fibroblast cultures from a patient presenting an epidermolysis bullosa dystrophica recessiva (EBDR) syndrome characterized, in particular, by blistering below the basal lamina observed by electron microscopy. The previously described increase in collagen production was confirmed and several other qualitative modifications of the secreted collagen were observed, including an underhydroxylation of lysine, a decrease in the type III/type I collagen ratio, and an increase in the rapidly degraded collagen. On the other hand, these fibroblasts were able to organize and contract collagen to form a dermal equivalent like normal fibroblasts. Normal keratinocytes can grow and form an epidermal sheet on the surface of these dermal equivalents including normal or pathological fibroblasts.

Cells, Cultured↗
PubMed1985

Prevention of recurrences in frequently relapsing herpes labialis with thymopentin. A randomized double-blind placebo-controlled multicenter study.

The present randomized, placebo-controlled double-blind multicenter study included a population of 36 subjects with frequent recurrences (at least once a month) of herpes labialis. Most of the patients had failed to respond adequately to previous treatment with other therapeutic tools, including acyclovir. Either 50 mg of thymopentin or of placebo was administered 3 times a week, by the subcutaneous route, for 6 weeks. Subsequently, the patients were observed for nearly 6 months on the average. The results achieved with thymopentin for the individual parameters were significantly superior to those obtained with placebo; thus significant improvement was seen in patients on thymopentin in the duration of the longest symptomfree period (prolonged from 2.1 weeks to 20.9 weeks, p = 0.000), in the number of relapses (reduced from 1.6 to 0.4 episodes/month, p = 0.001), and in the total duration of herpes symptoms per month (shortened from 2.0 to 0.3 weeks, p = 0.000). Placebo treatment also resulted in considerable improvement (p less than 0.05 or 0.01), but was significantly inferior to the improvement obtained with thymopentin. The longest symptomfree period in the placebo group was prolonged from 2.4 to 11.2 weeks. The number of relapses per month was reduced from 1.4 to 0.8, and the total duration of herpes symptoms per month from 2 to 0.9 weeks. The results of intergroup analyses, in which the observed parameters and the improvement achieved in either group were compared, significantly favored thymopentin treatment. The effect of thymopentin was in all but one parameters superior to that of placebo and highly significant (p less than 0.01).

Adjuvants, Immunologic↗
PubMed1983

Therapeutic use of TP5 (thymopoietin 32-36) in sarcoidosis of the skin.

TP5, a synthetic pentapeptide corresponding to thymopoietin 32-36, was administered alone to eight adult volunteer patients with sarcoidosis. A dose of 50 mg of TP5 was given iv, three times a week for 6 weeks, to three patients with erythema nodosum (EN) and bilateral hilar adenopathy, and to one patient with sarcoids of the skin; and for 12 weeks, to the other four patients with skin sarcoids. Before treatment and every 3 weeks thereafter clinical features; routine laboratory tests; tests for cellular immunity, humoral immunity, and auto immunity; IgE levels; and polymorphonuclear functions were recorded. EN disappeared in 3 weeks; hilar adenopathy improved or disappeared more slowly. Improvement of skin sarcoids was noted (lesions flattened or were cured). No side effects were observed. No evident changes in routine tests, humoral and auto immunity, IgE levels, and functions of polymorphonuclear leukocytes were observed. Cutaneous anergy to skin multi-tests was observed in seven patients before treatment, and was corrected with TP5 in six cases. In patients with low levels of peripheral blood T cells and suppressor T cells (as determined using specific monoclonal antibodies), a progressive normalization was obtained with TP5. These data support the efficacy of TP5 in sarcoidosis, although the action of the drug may be only temporary, as spontaneous remission may have occurred in this open trial of only eight cases.

Adult↗
PubMed1981

Sclerosing lipogranuloma of the male genitalia: ultrastructural study.

Ultrastructural study of a case of sclerosing lipogranuloma showed predominantly histiocytic-like cell infiltrate with numerous intracytoplasmic vacuoles of varied sizes without any limiting membrane and located in the deep dermis and subcutaneous fat. Fibroblasts appeared normal. Polymorphonuclear cells and macrophages were absent. This appearance was different from that described in 'classical' phagocytosis, mucopolysaccharidoses or polyvinylpyrrolidone storage syndrome.

Genital Diseases, Male↗
PubMed1980

[Antigenic determinants within immune complexes: similar and heterogeneous distribution in cutaneous vasculitis (author's transl)].

Twenty-one patients with various cutaneous vasculitis (8 with leukocytoclastic lesions, 5 with lymphocytic infiltration, 4 with anaphylactoid purpura, 2 with essential mixed cryoglobulinemia and 2 other cases) were studied for the presence and the characterization of circulating immune comlexes. Thirteen patients had circulating immune complexes evidenced by 2 p. 100 polyethylene glycol precipitation. A solid phase cross reaction applied to isolated complexes showed common antigenic determinants and/or antibody specificity in patients with different histopathological and clinical features. On the other hand, patients suffering from identical vasculitis possessed different determinants in their immune complexes. These findings are interpreted to indicate that the distribution of the complexed antigens does not square with a clinical classification.

Antigen-Antibody Complex↗